Valeur202320242025TTMFrais de vente, généraux et administratifs336.6 M560.7 M456.4 M435.1 MRecherche et développement————Résultat d'exploitation63.1 M-161.9 M-872.6 M-355.9 MTotal des produits hors exploitation7.7 M10.6 M-19.1 M-3.3 MCharges d'intérêts, nettes des intérêts capitalisés69.8 M———Résultat hors exploitation, hors charges d'intérêts-69 M-10.7 M-27 M-11.7 MRevenus/dépenses exceptionnels6.9 M21.3 M7.9 M8.4 MRésultat avant impôts1.1 M-275 M-983 M-447.3 MPart des actionnaires dans le résultat————Impôts4.5 M-3.5 M3.2 M-400 KIntérêts ne donnant pas le contrôle / intérêts minoritaires————Autres produits/charges après impôts1 M-9.3 M-4.5 M-4.6 MRésultat net avant activités abandonnées-3.4 M-271.5 M-986.2 M-446.9 MActivités abandonnées—-57 M0—Résultat net-3.4 M-328.5 M-986.2 M-446.9 MAjustement de dilution————Dividendes privilégiés————Résultat net dilué revenant aux actionnaires ordinaires-3.4 M-328.5 M-986.2 M-446.9 MBénéfice par action de base (BPA de base)-0.04-3.67-10.81-4.81Bénéfice par action dilué (BPA dilué)-0.04-3.67-10.81-4.81Nombre moyen d'actions de base en circulation88.8 M89.5 M——Nombre d'actions en circulation après dilution88.8 M89.5 M——EBITDA159.5 M-75 M-794.6 M-277.6 MEBIT63.1 M-161.9 M-872.6 M-355.9 MCoût des ventes2.59 B2.16 B2.22 B2.2 BAutres coûts des ventes2.59 B2.16 B2.22 B2.2 BAmortissements (flux de trésorerie)96.4 M86.9 M78 M78.3 M
Fortrea Holdings Inc. - Common Stock
Fortrea Holdings Inc. is an American contract research organization organized in Delaware and headquartered in Durham, North Carolina with operations in 90 countries. Its customers are primarily in the pharmaceutical, biotechnology, and medical device industries.
Its primary business is handling all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, and post-approval services. It handles regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. It focuses on oncology, central nervous system and neurodegenerative, rare diseases, and cell and gene therapies. In the five years ending in 2023, it conducted more than 5,850 clinical trials involving over 1 million subjects. It also conducted over 600 studies for medical device companies.
The company is one of the largest participants in the international primate trade and has been criticized for its animal testing practices, most specifically animal testing on non-human primates.